AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Black Diamond joins ArriVent in the PACC pack
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ESMO 2024 – Opdualag comes under fire
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
